HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $452,000 | -81.0% | 10,272 | -82.8% | 0.03% | -78.2% |
| Q1 2022 | $2,384,000 | +67.9% | 59,782 | +69.3% | 0.16% | -11.9% |
| Q4 2021 | $1,420,000 | +55.9% | 35,318 | +57.6% | 0.18% | +46.3% |
| Q3 2021 | $911,000 | -42.5% | 22,405 | -74.9% | 0.12% | -74.4% |
| Q4 2019 | $1,584,000 | +63.3% | 89,363 | +42.8% | 0.47% | +30.7% |
| Q3 2019 | $970,000 | -15.1% | 62,562 | -6.0% | 0.36% | -14.2% |
| Q2 2019 | $1,143,000 | +54.5% | 66,537 | +44.8% | 0.42% | -0.2% |
| Q1 2019 | $740,000 | -48.7% | 45,965 | -53.4% | 0.42% | +5.2% |
| Q4 2018 | $1,443,000 | +21.5% | 98,601 | +50.8% | 0.40% | +57.0% |
| Q3 2018 | $1,188,000 | +64.5% | 65,394 | +52.9% | 0.26% | +70.7% |
| Q2 2018 | $722,000 | +54.6% | 42,769 | +79.5% | 0.15% | +66.7% |
| Q1 2018 | $467,000 | +253.8% | 23,830 | +56.0% | 0.09% | +66.7% |
| Q2 2016 | $132,000 | – | 15,272 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |